COLCOT

• Research type

  Research Study

• Full title

  Colchicine Cardiovascular Outcomes Trial

• IRAS ID

  199215

• Contact name

  Maureen Travers

• Contact email

  Maureen.Travers@ggc.scot.nhs.uk

• Sponsor organisation

  Montreal Heart Institute

• Eudract number

  2014-005172-28

• Clinicaltrials.gov Identifier

  NCT02551094

• Duration of Study in the UK

  3 years, 10 months, 1 days

• Research summary

  Atherosclerosis (disease of the arteries) is the most frequent cause of myocardial infarction. Research has shown that inflammation plays a key role in manifestations of atherosclerosis and therefore it is likely that it is responsible for cardiovascular events like myocardial infarction.
  The main aim of this study is to determine whether long-term treatment with colchicine, an anti-inflammatory drug, reduces the recurrence rate of cardiovascular events in patients diagnosed with myocardial infarction. The other aims of the study are to determine the safety of long-term treatment with colchicine and the relation between soluble and genetic biomarkers (biological indicators) and the effects of the treatment.

• REC name

  West of Scotland REC 1

• REC reference

  16/WS/0132

• Date of REC Opinion

  19 Aug 2016

• REC opinion

  Further Information Favourable Opinion